Medical Cannabis Prescribing Safety: Guidelines, Risks, and Best Practices

Executive Summary

Medical cannabis prescribing safety has emerged as a critical regulatory and clinical challenge as jurisdictions worldwide expand patient access to cannabis-based medicines. The September 2026 disclosure by Jersey's Health Department of an investigation into a death involving medical cannabis has intensified scrutiny of prescribing protocols, patient monitoring systems, and the adequacy of clinical guidance for healthcare providers. Medical cannabis programs now operate in 38 U.S. states, three U.S. territories, and more than 50 countries, yet standardized safety frameworks remain fragmented. Physicians face the dual challenge of serving patients seeking alternatives to opioids and other pharmaceuticals while navigating incomplete clinical evidence, variable product quality, and the absence of FDA-approved dosing guidelines for most conditions. This topic encompasses drug interaction risks, contraindications in vulnerable populations, the role of state medical boards in oversight, and the tension between expanding access and ensuring patient safety. As medical cannabis markets mature and patient populations diversify to include elderly patients, those with complex comorbidities, and pediatric cases, the imperative for robust prescribing safety protocols has never been more urgent.

Why Medical Cannabis Prescribing Safety Matters

Approximately 7.3 million Americans held active medical cannabis registrations as of January 2026, representing a patient population larger than those taking many FDA-approved specialty pharmaceuticals. The economic scale is substantial: U.S. medical cannabis sales totaled $8.7 billion in 2025, according to industry analytics firm BDSA, with patients spending an average of $1,200 annually on cannabis medicines. Unlike recreational programs, medical cannabis serves clinically vulnerable populations—cancer patients undergoing chemotherapy, veterans with PTSD, elderly patients with chronic pain, children with treatment-resistant epilepsy, and individuals managing HIV/AIDS wasting syndrome. Healthcare providers bear direct responsibility for patient outcomes. In states like Ohio and Pennsylvania, physicians must complete state-mandated training before obtaining certificates to recommend medical cannabis, yet these programs vary dramatically in rigor and duration. The New York State Department of Health requires four hours of continuing medical education, while California imposes no specific training requirement. This inconsistency creates knowledge gaps that directly impact patient safety. The financial implications extend beyond patient spending. Medical malpractice insurers have begun adjusting premiums and coverage terms for physicians who recommend cannabis, reflecting uncertainty about liability exposure. A 2025 survey by the American Medical Association found that 43% of physicians who could legally recommend medical cannabis in their states declined to do so, citing inadequacy of clinical evidence and fear of regulatory or legal consequences. Patients face tangible risks. Cannabis interacts with cytochrome P450 enzymes, affecting metabolism of warfarin, clobazam, and numerous other medications. THC can exacerbate psychiatric conditions in predisposed individuals. Elderly patients metabolize cannabinoids differently than younger adults, yet age-specific dosing guidance remains largely absent from state medical cannabis programs. The death investigation disclosed by Jersey's Health Department in September 2026 underscores that these are not theoretical concerns but real clinical events requiring systematic response.

Background and History: The Evolution of Medical Cannabis Prescribing

The modern medical cannabis movement began with California's Proposition 215 in 1996, but prescribing safety protocols lagged behind access expansion for more than two decades.

1996-2003: The Compassionate Use Era

California's Compassionate Use Act, approved by voters on November 5, 1996, established the first state-legal medical cannabis program in the United States. The statute permitted physicians to "recommend" rather than "prescribe" cannabis—a distinction designed to avoid direct conflict with federal law under the Controlled Substances Act. The law imposed no specific safety protocols, dosing guidelines, or physician training requirements. Alaska, Oregon, and Washington followed with similar voter-approved initiatives between 1998 and 1999. These early programs operated with minimal regulatory infrastructure. Physicians provided handwritten recommendations on letterhead with no standardized format, no reporting to state databases, and no requirement to document qualifying conditions in detail. The lack of product testing standards meant patients consumed cannabis of unknown potency and potential contamination.

2003-2009: State Registry Systems Emerge

Hawaii became the first state to implement a patient registry system in 2000, requiring physicians to submit certification forms to the Department of Health. This model enabled state tracking of patient numbers and qualifying conditions, though it did not yet address prescribing safety directly. By 2009, 13 states had enacted medical cannabis laws, with registry systems becoming the norm. The U.S. Supreme Court's decision in Gonzales v. Raich (2005) affirmed federal authority to prosecute medical cannabis under the Commerce Clause, even in states with legal programs. This created ongoing tension between state medical practice and federal drug scheduling that persists today. The DEA's classification of cannabis as a Schedule I substance under 21 U.S.C. § 812 meant physicians could not write prescriptions in the traditional sense, limiting their ability to provide detailed dosing instructions through pharmacy systems.

2010-2013: Dispensary Regulation and Product Testing

Colorado's Amendment 20 implementation rules, finalized in 2010, introduced mandatory testing for mold, mildew, and pesticides in medical cannabis products sold through licensed dispensaries. This marked the first systematic effort to ensure product safety at the point of sale. The Colorado Department of Public Health and Environment established potency testing requirements in 2011, enabling patients and physicians to know THC and CBD concentrations. Michigan's medical cannabis program, approved by voters in 2008, faced legal challenges regarding caregiver cultivation limits and dispensary operations. The Michigan Supreme Court's 2013 decision in People v. McQueen clarified that the Michigan Medical Marihuana Act did not authorize commercial dispensaries, creating regulatory uncertainty that delayed safety infrastructure development.

2014-2016: Physician Training Requirements Introduced

New York's Compassionate Care Act, signed by Governor Andrew Cuomo on July 5, 2014, became the first medical cannabis law to mandate physician education. The statute required practitioners to complete a four-hour course approved by the New York State Department of Health covering pharmacology, contraindications, and adverse event reporting. The curriculum included instruction on drug interactions, appropriate patient selection, and documentation standards. Pennsylvania followed with the Medical Marijuana Act in 2016, requiring physicians to complete four hours of continuing education and register with the Department of Health before certifying patients. The Pennsylvania program also limited initial certifications to specific qualifying conditions and required follow-up visits within specified timeframes—the first state-level attempt to mandate ongoing patient monitoring.

2017-2020: Opioid Crisis Drives Policy Shifts

As opioid overdose deaths exceeded 70,000 annually in the United States by 2017, multiple states added chronic pain and opioid use disorder to qualifying condition lists. Illinois, Ohio, and Pennsylvania explicitly positioned medical cannabis as an opioid alternative in legislative findings. This policy shift brought new patient populations—often elderly individuals with complex medication regimens—into medical cannabis programs, heightening drug interaction concerns. Ohio's medical cannabis program, which began patient sales in January 2019, implemented a sophisticated tracking system requiring physicians to document all recommendations in a state database and mandating dispensaries to verify patient purchase limits. The Ohio Board of Pharmacy established a 90-day supply limit and required dispensaries to counsel patients on administration methods and potential side effects. The FDA's approval of Epidiolex (cannabidiol oral solution) in June 2018 for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome provided the first FDA-sanctioned dosing guidance for a cannabis-derived medication. Clinical trials supporting Epidiolex approval revealed significant drug interactions with clobazam and valproate, underscoring the importance of systematic safety monitoring.

2021-2024: International Frameworks and Adverse Event Reporting

The United Kingdom's National Institute for Health and Care Excellence (NICE) published comprehensive guidelines for cannabis-based medicinal products in November 2019, updated in 2021. These guidelines established evidence thresholds for prescribing, recommended specialist-only prescribing for most conditions, and required registration of all patients in a national database. The UK model influenced regulatory approaches in Australia, Germany, and other European jurisdictions. Germany's Federal Institute for Drugs and Medical Devices (BfArM) implemented mandatory adverse event reporting for medical cannabis in March 2022, requiring physicians to submit reports of serious adverse events within 15 days. By December 2023, the BfArM database contained more than 1,200 adverse event reports, with drug interactions and psychiatric effects representing the most common categories. In the United States, the DEA's August 2024 Notice of Proposed Rulemaking to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act raised questions about how rescheduling would affect prescribing practices. Schedule III classification would theoretically allow traditional prescriptions rather than recommendations, potentially enabling integration with pharmacy systems and prescription drug monitoring programs.

2025-Present: Death Investigations and Regulatory Response

Jersey's Health Department disclosure in September 2026 of an investigation into a death involving medical cannabis represents a critical inflection point. While details of the case remain under investigation, the announcement prompted immediate calls for enhanced prescribing protocols and patient monitoring systems. The incident occurred within a medical cannabis program that had served approximately 3,000 registered patients since its 2019 launch, according to Jersey government statistics.

Key Players in Medical Cannabis Prescribing Safety

State Medical Boards and Regulatory Agencies

State medical boards hold primary authority over physician conduct and prescribing practices. The Federation of State Medical Boards issued position statements in 2016 and updated in 2022 recommending that physicians who recommend medical cannabis establish a bona fide physician-patient relationship, perform a physical examination, document qualifying conditions, and maintain ongoing monitoring. However, enforcement varies dramatically. The California Medical Board has taken minimal disciplinary action related to medical cannabis recommendations, while the Ohio State Medical Board has sanctioned physicians for inadequate documentation and failure to conduct proper examinations. State health departments administer medical cannabis registries and establish qualifying conditions. The Pennsylvania Department of Health added anxiety disorders to the qualifying condition list in July 2019 over objections from medical professionals who cited limited evidence and potential for psychiatric adverse effects. The New York State Department of Health removed the requirement for in-person physician visits in March 2021, allowing telemedicine certifications—a policy that improved access but raised concerns about thoroughness of patient evaluation.

The Drug Enforcement Administration

The DEA maintains cannabis as a controlled substance and regulates research access. The agency's August 2024 proposal to reschedule cannabis to Schedule III would not legalize medical cannabis under federal law but would reclassify it alongside medications like ketamine and anabolic steroids. This rescheduling could affect how physicians document recommendations and whether medical cannabis qualifies for coverage under federal health programs. The DEA's administrative law judge hearings on rescheduling, scheduled to begin in December 2024, included testimony from medical professionals on prescribing safety implications.

The Food and Drug Administration

The FDA regulates cannabis-derived pharmaceuticals like Epidiolex and synthetic cannabinoids like dronabinol (Marinol). The agency has consistently stated that state medical cannabis products do not meet FDA approval standards and that physicians who recommend them operate outside the federal regulatory framework. The FDA's 2020 guidance on clinical trial design for cannabis-derived products established endpoints and safety monitoring protocols that could inform state-level prescribing practices, though states are not required to adopt them.

Medical Professional Organizations

The American Medical Association maintains that cannabis should remain a Schedule I substance until FDA approval processes are completed, creating tension with state medical cannabis programs. The American Academy of Family Physicians published clinical guidance in 2021 recommending that physicians who recommend medical cannabis screen for substance use disorders, assess psychiatric history, review all current medications for interaction potential, and document informed consent discussions covering risks and lack of FDA approval. The Society of Cannabis Clinicians, founded in 2004, provides continuing education for physicians and publishes clinical monographs on specific conditions. The organization's 2023 guidance on cannabis use in elderly patients recommended starting doses 50-75% lower than those for younger adults and emphasized cardiovascular risk assessment.

Patient Advocacy Organizations

Americans for Safe Access, founded in 2002, has advocated for patient protections and access expansion while also supporting quality control standards and physician education requirements. The organization's 2024 report on medical cannabis program design identified prescribing safety protocols as a critical gap in most state programs. The Epilepsy Foundation supported FDA approval of Epidiolex while maintaining that some patients require whole-plant cannabis products not captured by the approved medication. This position reflects the tension between evidence-based medicine and patient-reported benefits of products that lack rigorous clinical trial data.

Legal and Regulatory Framework

Medical cannabis prescribing operates in a complex legal environment where state authorization conflicts with federal prohibition under the Controlled Substances Act. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., classifies cannabis as a Schedule I substance, defined as having high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. This classification makes it illegal for physicians to write prescriptions for cannabis under federal law. State medical cannabis programs circumvent this prohibition by authorizing physicians to provide "recommendations" or "certifications" rather than prescriptions—a distinction upheld in Conant v. Walters (9th Cir. 2002), which found that physician recommendations constitute protected speech under the First Amendment. The Rohrabacher-Farr Amendment, first enacted in 2014 and renewed annually through continuing resolutions, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. This provision does not legalize medical cannabis under federal law but provides practical protection for state-licensed operators and registered patients. State medical practice acts govern physician conduct. In most states, medical boards can discipline physicians for prescribing practices that fall below the standard of care, even for substances legal under state law. The standard of care for medical cannabis remains poorly defined due to limited clinical trial data. Courts have generally deferred to medical board expertise in determining whether a physician's cannabis recommendations met professional standards. HIPAA privacy regulations apply to medical cannabis patient records, but the federal prohibition creates complications. The Department of Health and Human Services has not issued specific guidance on whether state medical cannabis registries constitute covered entities under HIPAA. Most states treat registry data as confidential health information with protections exceeding HIPAA minimums. Product liability law presents unresolved questions. If a patient suffers harm from contaminated or mislabeled medical cannabis, traditional pharmaceutical liability frameworks may not apply because the product lacks FDA approval. State-licensed dispensaries and cultivators may face liability under state consumer protection statutes, but federal courts have dismissed some cannabis-related product liability claims on grounds that the underlying conduct violates federal law.

State-by-State Prescribing Safety Protocols

Prescribing safety requirements vary dramatically across the 38 states with medical cannabis programs, creating a patchwork of patient protections.

California

California imposes no mandatory physician training, no requirement for ongoing patient monitoring, and no limits on the number of patients a physician may certify. The state's Medicinal and Adult-Use Cannabis Regulation and Safety Act requires product testing for pesticides, heavy metals, and microbial contaminants, but physicians bear no responsibility for verifying product safety. The California Medical Board has issued guidance recommending but not requiring that physicians establish a treatment plan and document informed consent.

New York

New York requires physicians to complete a four-hour Department of Health-approved course before registering as medical cannabis practitioners. The curriculum covers endocannabinoid system pharmacology, drug interactions, contraindications in pregnancy and psychiatric disorders, and documentation requirements. Physicians must recertify patients at intervals not exceeding 12 months and document the patient's response to treatment. The state's registry system tracks all certifications and dispensary purchases, enabling identification of patients obtaining recommendations from multiple physicians.

Ohio

Ohio mandates a two-hour continuing education course for physicians seeking certificates of registration to recommend medical cannabis. The Ohio State Medical Board requires physicians to review the state's prescription drug monitoring program database before initial certification and annually thereafter to identify potential substance use disorders or doctor shopping. Physicians must document a qualifying condition diagnosis, previous treatments attempted, and rationale for recommending cannabis. The state limits patients to a 90-day supply and requires dispensaries to provide written information on administration methods and potential adverse effects.

Pennsylvania

Pennsylvania requires four hours of continuing education covering pharmacology, contraindications, and side effects. Physicians must register with the Department of Health and maintain records of all patient certifications for at least five years. The state initially required in-person examinations but shifted to allowing telemedicine certifications in 2020. Pennsylvania's registry system flags patients with certifications from multiple physicians, triggering Department of Health review for potential abuse.

Florida

Florida requires physicians to complete a two-hour course and examination administered by the Florida Medical Association or the Florida Osteopathic Medical Association. The state's "low-THC cannabis" provisions for certain conditions require physicians to submit quarterly reports on patient outcomes. For full-strength medical cannabis, physicians must enter orders into the state's Medical Marijuana Use Registry specifying the allowable milligrams of THC per day—a dosing specificity unusual among state programs. Florida law requires a 30-day waiting period between physician certification and registry card issuance for most patients, intended to ensure deliberate decision-making.

Massachusetts

Massachusetts requires no specific physician training but mandates that certifying physicians hold an active Massachusetts medical license and have a bona fide physician-patient relationship with the patient. The state's Cannabis Control Commission requires written certifications to include the qualifying condition, other treatment options considered, and potential risks and benefits. Massachusetts law prohibits physicians from holding financial interests in medical cannabis dispensaries, addressing conflict-of-interest concerns.

Illinois

Illinois requires physicians to register with the Department of Public Health but imposes no mandatory training. The state's Compassionate Use of Medical Cannabis Program Act requires physicians to document that the patient has a debilitating medical condition and that the benefits of medical cannabis would likely outweigh the risks. Illinois added opioid use disorder as a qualifying condition in 2019, requiring physicians to verify that patients have attempted other treatments before certifying cannabis use.

Market and Business Implications

Prescribing safety protocols directly affect multi-state operator revenue models, insurance coverage decisions, and capital allocation in the medical cannabis sector. States with stringent physician training requirements and patient monitoring systems tend to have smaller medical cannabis patient populations relative to total state population. New York's medical program served approximately 185,000 registered patients as of January 2026, representing 0.9% of the state's population, while California's program served an estimated 1.2 million patients, approximately 3.0% of the state's population. The difference reflects not only program maturity but also the relative ease of obtaining certifications. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries derive 35-45% of revenue from medical sales, according to 2025 financial disclosures. These companies face different compliance costs across states. In Ohio, dispensaries must employ pharmacists or pharmacy technicians to counsel patients, adding $75,000-$95,000 in annual labor costs per location. In California, no such requirement exists. These cost differentials affect market entry decisions and pricing strategies. Insurance coverage for medical cannabis remains virtually nonexistent in the United States due to federal prohibition. However, some health savings account administrators have begun allowing HSA funds to be used for Epidiolex and other FDA-approved cannabis-derived medications, creating a potential pathway for broader coverage if rescheduling occurs. Workers' compensation insurers in New Mexico and Minnesota have covered medical cannabis for injured workers in limited circumstances, establishing reimbursement precedents that could expand with enhanced safety protocols. Physician practice economics influence prescribing patterns. Some physicians charge $200-$400 for initial medical cannabis certifications and $100-$200 for renewals, creating financial incentives that may conflict with rigorous patient evaluation. States like Pennsylvania that require documentation of previous treatments attempted impose implicit costs on physicians through increased time per patient encounter. A 2024 analysis in the Journal of Medical Economics found that physicians in states with comprehensive documentation requirements certified 40% fewer patients annually than those in states with minimal requirements, suggesting that safety protocols affect practice volume. Liability insurance costs for physicians who recommend medical cannabis vary by state and carrier. A 2025 survey by Physician Insurers Association of America found that 62% of medical malpractice carriers impose no premium surcharge for cannabis recommendations, while 23% add surcharges of $500-$2,500 annually. The remaining 15% exclude cannabis-related claims from coverage entirely. This variability reflects uncertainty about actual liability exposure and the absence of significant case law on medical cannabis malpractice.

What Medical Experts and Researchers Say

Clinical experts emphasize that the absence of randomized controlled trial data for most medical cannabis uses creates inherent prescribing challenges that safety protocols can only partially address. Dr. Kevin Hill, Director of the Division of Addiction Psychiatry at Beth Israel Deaconess Medical Center, stated in a 2024 interview with the New England Journal of Medicine that physicians recommending medical cannabis operate with far less evidence than required for FDA-approved medications. According to Hill, the lack of standardized products means that even when clinical trials demonstrate efficacy for a specific cannabis formulation, patients may receive products with different cannabinoid ratios and terpene profiles. Dr. Danielle Ofri, writing in the Journal of the American Medical Association in 2023, described the ethical tension physicians face between patient autonomy and evidence-based practice. According to Ofri, patients often arrive at appointments having researched cannabis online and requesting certifications for conditions with minimal clinical evidence. Ofri noted that overly restrictive prescribing protocols may drive patients to unregulated markets, while overly permissive approaches may expose patients to preventable harms. Research published in JAMA Internal Medicine in 2022 by Vozoris et al. found that cannabis use was associated with increased risk of emergency department visits and hospitalizations among older adults, with hazard ratios of 1.22 and 1.15 respectively. The study, which analyzed health records of 4,651 adults aged 65 and older in Ontario, Canada, suggested that age-specific prescribing guidelines are necessary but largely absent from current medical cannabis programs. A 2023 systematic review in the British Medical Journal by Stevens and Rahn examined drug interactions between cannabis and commonly prescribed medications. The review identified clinically significant interactions with warfarin, clobazam, tacrolimus, and theophylline, all mediated through cytochrome P450 enzyme inhibition. The authors recommended that physicians review all patient medications before recommending cannabis and monitor international normalized ratio (INR) levels in patients taking warfarin. Dr. Igor Grant, Director of the Center for Medicinal Cannabis Research at the University of California San Diego, testified before the California State Assembly in 2024 that physician education requirements should include training on identifying cannabis use disorder. According to Grant, approximately 9% of adults who use cannabis develop use disorder, rising to 17% among those who initiate use in adolescence. Grant stated that physicians must balance therapeutic benefits against addiction risk, particularly in patients with personal or family history of substance use disorders. The American College of Physicians published a position paper in 2024 calling for federal rescheduling to enable rigorous clinical research while also recommending that states implement mandatory adverse event reporting systems. According to the position paper, the absence of systematic safety monitoring means that rare but serious adverse events may go undetected until significant patient harm has occurred.

Drug Interactions and Contraindications

Cannabis affects hepatic enzyme systems responsible for metabolizing more than 60% of prescription medications, creating interaction risks that many physicians and patients underestimate. THC and CBD inhibit cytochrome P450 enzymes CYP3A4, CYP2C9, and CYP2C19, which metabolize medications including warfarin, clopidogrel, omeprazole, diazepam, and numerous others. A patient taking warfarin who begins using high-CBD cannabis may experience elevated INR levels and increased bleeding risk if the physician does not adjust warfarin dosing. Conversely, discontinuing cannabis may reduce INR levels, increasing thrombosis risk. Clobazam, an anti-seizure medication, shows particularly significant interactions with CBD. The FDA-approved Epidiolex prescribing information includes a black box warning about elevated liver enzymes when CBD is co-administered with valproate and recommends clobazam dose reduction when used with CBD. These interactions, documented in rigorous clinical trials, likely occur with non-FDA-approved CBD products, yet many state medical cannabis programs do not require physicians to screen for anti-seizure medication use before certification. Cannabis can exacerbate psychiatric conditions. Meta-analyses have found associations between cannabis use and increased risk of psychosis, with stronger associations in individuals with genetic vulnerability. The American Psychiatric Association recommends against cannabis use in patients with schizophrenia or bipolar disorder, yet some state qualifying condition lists include PTSD and anxiety disorders without requiring psychiatric evaluation or excluding patients with psychotic disorder history. Cardiovascular effects present risks in elderly patients. Cannabis causes transient tachycardia and orthostatic hypotension, potentially triggering adverse events in patients with coronary artery disease or arrhythmias. A 2019 study in the Journal of the American College of Cardiology found that cannabis use was associated with increased risk of acute myocardial infarction in the hour following use, with risk highest in older adults and those with pre-existing cardiovascular disease. Pregnancy and lactation represent clear contraindications. The American College of Obstetricians and Gynecologists recommends against cannabis use during pregnancy due to associations with low birth weight and potential neurodevelopmental effects. THC is excreted in breast milk, raising concerns about infant exposure. Despite these recommendations, some state medical cannabis programs do not explicitly prohibit certifications for pregnant or breastfeeding patients.

Patient Monitoring and Adverse Event Reporting

Most U.S. state medical cannabis programs lack systematic adverse event reporting requirements, creating a critical gap in safety surveillance. Unlike FDA-approved medications, which are subject to mandatory adverse event reporting under the FDA Amendments Act of 2007, state medical cannabis products have no federal reporting pathway. Some states have established voluntary reporting systems, but participation rates remain low. Pennsylvania's adverse event reporting system, launched in 2019, received fewer than 50 reports in its first three years despite serving more than 400,000 registered patients, according to Department of Health data. Germany's mandatory reporting system provides a model. The BfArM requires physicians to report serious adverse events—defined as death, life-threatening events, hospitalization, or persistent disability—within 15 days of becoming aware of them. The system captured 1,247 reports between March 2022 and December 2023, with psychiatric effects (22%), drug interactions (18%), and cardiovascular events (12%) representing the most common categories. This data has informed clinical guidance and physician education programs. Israel's medical cannabis program, which serves approximately 130,000 patients, requires physicians to document patient outcomes at each follow-up visit in a national database. The Israeli Ministry of Health analyzes this data to identify safety signals and publishes annual reports on adverse events and treatment patterns. This systematic monitoring has revealed that elderly patients experience higher rates of dizziness and falls, leading to revised dosing recommendations. The lack of standardized outcome measures hampers safety monitoring even in states with reporting systems. Unlike pharmaceutical trials that use validated instruments to measure efficacy and safety, medical cannabis programs rarely specify which outcomes physicians should track. Some physicians assess pain using numeric rating scales, while others use functional measures or patient global impression of change. This heterogeneity makes it difficult to aggregate data across providers or identify safety signals.

Telemedicine and Remote Prescribing Challenges

The COVID-19 pandemic accelerated adoption of telemedicine for medical cannabis certifications, raising questions about the adequacy of remote patient evaluation. Before 2020, most states required in-person physician examinations before initial medical cannabis certification. The pandemic prompted emergency orders allowing telemedicine certifications in New York, Pennsylvania, Ohio, and other states. Many states made these allowances permanent, citing improved access for rural patients and those with mobility limitations. Critics argue that telemedicine certifications may not enable adequate assessment of contraindications. Physical examination findings such as tachycardia, orthostatic hypotension, or signs of substance use disorder may not be apparent in video consultations. A 2023 study in the Journal of Telemedicine and Telecare found that physicians conducting telemedicine medical cannabis evaluations spent an average of 11 minutes per patient, compared to 23 minutes for in-person evaluations, raising concerns about thoroughness. Online certification services have proliferated, with some offering same-day approvals and charging fees as low as $99. These services typically employ physicians who conduct brief video consultations and certify patients for broad qualifying conditions like chronic pain. State medical boards have investigated some online certification services for inadequate patient evaluation, but enforcement remains inconsistent. The DEA's Ryan Haight Online Pharmacy Consumer Protection Act of 2008, codified at 21 U.S.C. § 829, generally requires in-person medical evaluation before prescribing controlled substances via telemedicine. However, this statute applies to prescriptions, not recommendations, and cannabis remains federally illegal regardless of scheduling. If cannabis is rescheduled to Schedule III, the Ryan Haight Act could potentially require in-person evaluations for medical cannabis, though legal analysis on this question remains unsettled.

Pediatric Prescribing Considerations

Medical cannabis use in children presents unique safety challenges due to ongoing neurodevelopment and limited pediatric clinical trial data. Epidiolex approval for pediatric seizure disorders established that cannabinoids can be used safely in children under specific circumstances, but the clinical trials supporting approval involved highly selected patient populations with treatment-resistant epilepsy. The trials excluded children with significant psychiatric or developmental comorbidities, limiting generalizability. State medical cannabis programs vary in pediatric protections. Minnesota requires two physician certifications for patients under 18, with at least one from a pediatric subspecialist. New York requires parental consent and designation of a caregiver to obtain and administer medical cannabis. California imposes no special requirements for pediatric patients beyond those for adults. The American Academy of Pediatrics opposes medical cannabis for children except in the context of rigorous clinical trials, citing concerns about neurodevelopmental effects and the absence of safety data for most conditions. A 2023 AAP policy statement noted that adolescent cannabis use is associated with altered brain development, reduced educational attainment, and increased risk of psychiatric disorders. Dosing in children presents particular challenges. Pediatric patients metabolize cannabinoids differently than adults, yet most medical cannabis products are formulated for adult use. Weight-based dosing guidance exists for Epidiolex but not for non-FDA-approved products. Case reports have documented accidental pediatric overdoses from edible cannabis products, with symptoms including lethargy, ataxia, and respiratory depression.

What's Next: Future Developments and Decision Points

Multiple regulatory and legislative processes underway in 2026 will shape medical cannabis prescribing safety protocols for the next decade. The DEA's rescheduling process represents the most significant federal development. If cannabis is rescheduled to Schedule III, physicians could theoretically write traditional prescriptions, enabling integration with pharmacy systems and prescription drug monitoring programs. However, rescheduling would not legalize medical cannabis under federal law—it would remain a controlled substance requiring FDA approval for legal prescription. The administrative law judge hearings, which began in December 2024 and continued through 2025, included extensive testimony on medical use and safety. A final rule is expected in 2027, though legal challenges could delay implementation. Several states are considering mandatory physician training legislation. A bill introduced in the California State Assembly in January 2026 would require eight hours of continuing education for physicians who certify more than 25 patients annually. The legislation, supported by the California Medical Association, faces opposition from patient advocacy groups who argue it will reduce access. Similar bills are under consideration in Michigan and Arizona. The National Academies of Sciences, Engineering, and Medicine is conducting a comprehensive review of cannabis and cannabinoid research, with a report expected in late 2026. The review will assess evidence for therapeutic effects and health risks across multiple conditions and populations. Previous National Academies reports have influenced state policy and medical professional organization positions. International developments may inform U.S. policy. The United Kingdom's National Institute for Health and Care Excellence is updating its cannabis-based medicinal products guidelines in 2026, with particular focus on chronic pain and psychiatric conditions. Germany is evaluating data from its mandatory adverse event reporting system to determine whether additional prescribing restrictions are necessary. These international experiences provide natural experiments that U.S. policymakers can study. Technology solutions are emerging. Several companies are developing clinical decision support tools that integrate with electronic health records to flag drug interactions, contraindications, and dosing concerns when physicians consider medical cannabis recommendations. The Ohio State Medical Board is piloting integration of the state's medical cannabis registry with the prescription drug monitoring program to enable comprehensive medication review. Patient registries and observational studies are expanding. The Medical Cannabis Outcomes Research Registry, launched by the Society of Cannabis Clinicians in 2024, aims to enroll 50,000 patients across multiple states to track outcomes and adverse events. While observational data cannot replace randomized controlled trials, large registries can identify safety signals and inform clinical practice.

Clinical Best Practices and Emerging Standards

Despite regulatory fragmentation, consensus is emerging among medical professionals on core elements of safe medical cannabis prescribing. Comprehensive patient evaluation should include medical history, psychiatric history, substance use history, current medications, and assessment for contraindications. The Society of Cannabis Clinicians recommends screening tools including the Cannabis Use Disorder Identification Test (CUDIT-R) and the Patient Health Questionnaire-9 (PHQ-9) for depression. Informed consent discussions should cover the lack of FDA approval for most uses, potential adverse effects, drug interaction risks, the possibility of cannabis use disorder, and legal implications including employment and driving restrictions. Documentation of informed consent protects both patients and physicians. Start low and go slow dosing principles apply particularly to elderly patients and those new